Ledipasvir + Sofosbuvir buy
Hepcinat LP Tablets
"Hepcinat LP" Sofosbuvir + Ledipasvir "400mg + 100mg" Trade Information Minimum Order Quantity 1.00 Unit of Measure Piece/Pieces Payment Terms Paypal, Others Delivery Time 7-15 Days Main Export Market(s) Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa Main Domestic Market All India Ledipasvir & Sofosbuvir Export Countries Details: Countries: Russsia, Ukrain, Korea, Ajbakistan, Kajistan, Romania, Poland, USA, [...]
Hepcinat LP Trade Information
|Minimum Order Quantity||1.00||Unit of Measure||Piece/Pieces|
|Payment Terms||Paypal, Others||Supply Ability||As Per Requirement Per Week|
|Delivery Time||7-15 Days||Packaging Details||Carton Boxes Packaging.|
|Main Export Market(s)||Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa||Main Domestic Market||All India|
|Certifications||Certified Products.||New cell 3||New cell 4|
Hepcinat lp Tablets Suppliers & Exporters Price in India
We have been marked down as a noted organization engaged in offering Ledipasvir and Sofosbuvir Tablets. The tablets are indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Our expert agents procure these tablets from the most authentic vendors of the market. Ledipasvir and Sofosbuvir Tablets contained 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet. We offer these tablets at market leading prices to clients.
- Taken orally once daily
- Low indication of side effects
- Effective anti viral drug
Online Buy Hepcinat LP Tablets from India
Product DescriptionHepcinat LP is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration.Each film, coated tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
INDICATIONS AND USAGE
Hepcinat LP is indicated for the treatment of choronic hepatitis C (CHC) genotype 1 infection in adults.
DOSAGES AND ADMINISTRATION
Recommended Dosage in Adults
Hepcinat LP is two-drug fixed-dose combination product that contained 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet.The recommended dosages of Hepcinat LP is one tablet taken orally once daily with or without food.
Duration of treatment
Relapse rates are affected by baseline host and viral factors and differ between treatment durations for certain subgroups. Below provides the recommended Hepcinat LP treatment durations for treatment-naive and treatment-experienced patients and those with and without cirrhosis.
Recommended Treatment Duration for Hepcinat LP in Patients with CHC Genotype 1
|Patient Population||Recommended Treatment Duration|
|Treatment-naive with or without cirrhosis||12 weeks*|
|Treatment-experienced** without cirrhosis||12 weeks|
|Treatment-experienced** with cirrhosi||24 weeks|
*Hepcinat LP for 8 weeks can be considered in treatment-naÃƒ¯ve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/ mL .*Treatment-experienced patients who have failed treatment with either peginterferon alfa+ribavirin or an HCV protease inhibitor + peginterferon alfa + ribavirin.
DOSAGES FORMS AND STERENGTHS
Hepcinat LP is available as Green colored, oval shaped, film coated tablet debossed with one side and plain on other side of the tablet.Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
No contraindications have been identified.
WARNINGS AND PRECAUTIONS
Serious Symptomatic Bradycardia When Coadministered with Amiodarone
Postmarketing cases of symptomatic bradycardia,as well as fetal cardiac arrest and cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with Ledipasvir + Sofosbuvir. Bradycardia has generally occurred within hours to days, btus cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone.Bradycardia generally resolved after discontinuation of HCV treatment.The mechanism for this effect is unknown.
Clinical Trials Experience